PFC update

Renewal is a wide range of medicines and parapharmaceuticals for specialized applications and daily solutions to the health problems of the whole family.

Available original products and INN generics in a technological form are manufactured in accordance with world standards of good manufacturing practice and quality control.

History

2023: First place in the number of clinical drug trials

At the end of 2023, 761 clinical trials of drugs were approved in Russia. Domestic pharmaceutical companies are replacing foreign drugs in terms of the number of studies carried out, and European and American organizations are replaced by manufacturers from the SCO and EAEU countries. This is stated in a study by the analytical firm Sciencefiles, the results of which were published in early February 2024.

The report says that in 2023, among domestic companies that received the most approvals in clinical drug trials, the leader changed. If in 2022 the first position was taken by Promomed with 51 projects, then in 2023 the Update company with 45 studies broke out to the top of the rating. In second place, as in 2022, was Pharmsintez - 39 projects, in third - Amedart with 34 studies. Read more here.